Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Pacira BioSciences's price to sales ratio was 1.9× on Nov 11, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 1.0× to 6.3×, with a median of 1.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.9× | +0.4 |
| 2025 | Dec 31, 2025 | 1.6× | +0.3 |
| 2024 | Dec 31, 2024 | 1.3× | −1.1 |
| 2023 | Dec 29, 2023 | 2.4× | −0.4 |
| 2022 | Dec 30, 2022 | 2.7× | −2.5 |
| 2021 | Dec 31, 2021 | 5.2× | −0.9 |
| 2020 | Dec 31, 2020 | 6.2× | +1.4 |
| 2019 | Dec 31, 2019 | 4.8× | −0.7 |
| 2018 | Dec 31, 2018 | 5.5× | −1.1 |
| 2017 | Dec 29, 2017 | 6.6× | +2.2 |
| 2016 | Dec 30, 2016 | 4.4× | −3.1 |
| 2015 | Dec 31, 2015 | 7.5× | −11.4 |
| 2014 | Dec 31, 2014 | 18.8× | −12.0 |
| 2013 | Dec 31, 2013 | 30.9× | +13.6 |
| 2012 | Dec 31, 2012 | 17.3× | +6.3 |
| 2011 | Dec 30, 2011 | 10.9× | – |
See a number that looks wrong?